Clinical Obesity Research Panel (CORP)
Background
The NIDDK Clinical Obesity Research Panel (CORP) is the successor to the National Task Force on Prevention and Treatment of Obesity, which was in existence from June 1991 until June 2003. The NIDDK CORP, composed of leading obesity researchers and clinicians, is charged with providing advice to the NIDDK Advisory Council on important clinical research needs related to obesity prevention and treatment, including their relative priority and costs, and identifies concepts for future clinical studies of obesity. The CORP serves in an advisory capacity to the Weight-control Information Network and may suggest topics for NIDDK-sponsored workshops and develop papers on topics related to clinical aspects of obesity. The CORP is placed organizationally under the auspices of the NIDDK Advisory Council and a member of the NIDDK Advisory Council serves on the CORP as a liaison member.
Roster
|
Steven N. Blair, PED
Director of Epidemiology
Cooper Institute
12330 Preston Road
Dallas, TX 75230
Robert H. Eckel, MD
Department of Medicine
University of Colorado Health Sciences Center
4200 E 9th Avenue
Denver, CO 80262
Matthew W. Gillman, MD, SM
Director, Obesity Prevention Program
Associate Professor
Department of Ambulatory Care and Prevention
Harvard Medical School/Harvard Pilgrim Health Care
133 Brookline Avenue, 6th Floor
Boston, MA 02215
Lee M. Kaplan, MD, PhD
Associate Professor of Medicine
Director, Weight Center
50 Staniford St, 4th Floor
Boston, MA 02114
Samuel Klein, M.D.
Professor of Medicine and Nutritional Science
Director, Center for Human Nutrition
Washington University School of Medicine
660 S. Euclid Avenue
Campus Box 8031
St. Louis, MO 63110
Rudolph L. Leibel, M.D.
Professor of Pediatrics and Medicine
Head Division of Molecular Genetics
Columbia University College of Physicians
And Surgeons , Box 10
Russ Berrie Medical Science Pavilion
1150 Nicholas Avenue
New York, NY 10032 |
Nico Pronk, Ph.D., FACSM, FAWHP
Vice President, Center for Health Promotion
Research Investigator, HealthPartners Research Foundation
HealthPartners
8100 34th Avenue South
P.O. Box 1309
Minneapolis, MN 55440-1309
Alan R. Shuldiner, MD
John Whitehurst Professor of Medicine
Head, Division of Endocrinology, Diabetes and Nutrition
Director, Program in Genetics and Genomic Medicine
University of Maryland School of Medicine
Howard Hall, Room 494
660 Redwood St
Baltimore, MD 21202
Delia Smith West, PhD
Professor, Health Behavior
College of Public Health
4301 West Markham St, #820
Little Rock, AR 72205
|
[Top]
Contact
For more information, please contact the Executive Director of the CORP, Dr. Susan Yanovski.
Reports
- Very Low-Calorie Diets
Objective: To provide an overview of the published scientific information on the safety and efficacy of very low-calorie diets (VLCDs) and to provide rational recommendations for their use.
JAMA. 1993;270:967-974.
Reprints available from: Weight-control Information Network
- Weight Cycling
Objective: To address concerns about the effects of weight cycling and to provide guidance on the risk-to-benefit ratio of attempts at weight loss, given current scientific knowledge.
JAMA, 1994;272:1196-1202.
Reprints available from: Weight-control Information Network
- Towards Prevention of Obesity: Research Directions
Objective: The research initiatives and future directions presented in this paper were developed by The National Task Force on Prevention and Treatment of Obesity, appointed by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health. Five conceptual goals for obesity research were formulated for translation into action over the long term. These goals reflect a developing convergence of ideas from diverse sectors of the obesity research community and provide the overall direction for future research emphases.
Obesity Research, 1994;6:571-584.
Reprints available from: Weight-control Information Network
- Long-term Pharmacotherapy in the Management of Obesity
Objective: To examine the rationale for long-term use of medications in the management of obesity, to provide an overview of published scientific information on their safety and efficacy, and to provide guidance to patients and practitioners regarding risks and benefits of treatment.
JAMA, 1996;276:1907-1915.
Reprints available from: Weight-control Information Network
[Top]
Page last updated: October 24, 2008
